Nektar Therapeutics (NKTR) Amortizatization of Intangibles (2024 - 2026)
Nektar Therapeutics' quarterly Amortizatization of Intangibles came in at -$1.7 million in Q1 2026, down 25.6% year-on-year from -$2.2 million in Q1 2025, and up 11.92% quarter-over-quarter from -$1.9 million in Q4 2025.
Nektar Therapeutics has reported Amortizatization of Intangibles for 3 years, with the latest figure at -$1.7 million in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 25.6% year-over-year to -$1.7 million; the trailing twelve-month figure through Mar 2026 stood at -$5.9 million (up 22.02% YoY), and the FY2025 full-year result was -$5.5 million, up 40.36% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at -$1.7 million, up from -$1.9 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was -$869000.0 in Q2 2025, with the low at -$3.1 million in Q1 2024.
- Average Amortizatization of Intangibles over 3 years is -$1.8 million, with a median of -$1.7 million recorded in 2026.
- Year-over-year, Amortizatization of Intangibles surged 66.37% in 2025 and dropped 25.6% in 2026.
- Tracing NKTR's Amortizatization of Intangibles over 3 years: stood at -$1.5 million in 2024, then slipped by 23.08% to -$1.9 million in 2025, then rose by 11.92% to -$1.7 million in 2026.
- The last three Amortizatization of Intangibles figures came in at -$1.7 million (Q1 2026), -$1.9 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Nektar Therapeutics | 1.60 Bn | 1.04 Bn | 3.16 Mn | -1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.66 Mn |
| Mar 31, 2026 | -1.66 Mn |
| Dec 31, 2025 | -1.89 Mn |
| Dec 31, 2025 | -1.89 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | -869,000.00 |
| Jun 30, 2025 | -869,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -2.06 Mn |
| Sep 30, 2024 | -2.06 Mn |
| Jun 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -2.58 Mn |
| Mar 31, 2024 | -3.06 Mn |
| Mar 31, 2024 | -3.06 Mn |